DURECT (DRRX) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRRX shares.
View DRRX analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1 year price targets for DURECT's stock. Their DRRX share price forecasts range from $32.00 to $44.00. On average, they predict the company's share price to reach $36.25 in the next twelve months. This suggests a possible upside of 542.7% from the stock's current price.
View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts.

DURECT's stock was trading at $3.46 at the start of the year. Since then, DRRX shares have increased by 63.0% and is now trading at $5.64.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our DRRX earnings forecast.

DURECT Co. (NASDAQ:DRRX) issued its earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 130.41% and a negative net margin of 187.82%. During the same period in the prior year, the firm posted ($0.50) EPS.

DURECT's stock reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

DURECT's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.96%), Armistice Capital LLC (2.49%), CM Management LLC (1.63%), Beirne Wealth Consulting Services LLC (1.16%), Renaissance Technologies LLC (1.12%) and Geode Capital Management LLC (0.88%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito.
View institutional ownership trends.

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRRX stock can currently be purchased for approximately $5.64.

DURECT (NASDAQ:DRRX) has a market capitalization of $138.12 million and generates $19.28 million in revenue each year. The specialty pharmaceutical company earns $-35,330,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.